Chinese Health: Announcement on the estimated guarantee amount for subsidiaries in 2026
Securities code: 301408 Securities abbreviation: Chinese Health Announcement number: 2026-013
Anhui Chinese Health Pharmaceutical Co., Ltd.
Announcement on the estimated guarantee amount for subsidiaries in 2026
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete and does not contain any false records, misleading statements or major omissions.
Risk warning:
After this guarantee line takes effect, the company's effective guarantee line for subsidiaries with asset-liability ratios exceeding 70% will exceed 50% of the company's latest audited net assets. The aforementioned guarantee amount is estimated to ensure that the company and its subsidiaries apply for comprehensive bank credit needs from business-related parties, and the financial risks are within the company's controllable range. Investors are advised to pay full attention to guarantee risks.
The 14th meeting of the fifth board of directors of Anhui Huaren Health Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was held on April 23, 2026, and the "Proposal on the Estimated Guarantee Amount for Subsidiaries in 2026" was reviewed and approved. The specific situation is announced as follows:
1. Overview of guarantee situation
In order to meet the capital needs for daily operations and business development of the company and its subsidiaries (including wholly-owned, holding and subsidiaries newly established or incorporated within the authorization period, the same below), ensure that the company and its subsidiaries apply for comprehensive bank authorization from business related parties (including but not limited to banks, financial institutions and other business partners). It is expected that the smooth development of credit cards (including but not limited to handling RMB or foreign currency working capital loans, project loans, M&A loans, trade financing, bank acceptance bills, letters of credit, letters of guarantee, bill discounting, factoring, export bills, forward foreign exchange settlement and sales, and derivative products and other related businesses) or other business matters, is expected to In 2026, the company will provide guarantees (or counter-guarantees) for subsidiaries at all levels within the scope of consolidated statements, and mutual guarantees between subsidiaries at all levels within the scope of consolidated statements will not exceed a guarantee limit of RMB 2 billion (including equivalent foreign currencies, the same below). The guarantee methods include but are not limited to guarantees, mortgages, pledges, etc. At the same time, as long as the total guarantee limit does not exceed the above, the guarantee limit can be adjusted among subsidiaries (including newly added or newly established subsidiaries) within the current scope of consolidated statements based on actual operating needs. The actual guarantee amount shall be subject to the final signed guarantee contract.
The expected guarantee limit is valid for 12 months from the date of review and approval at the company's 2025 annual shareholders' meeting, and the limit can be recycled within the authorization period.
The estimated situation of the above guarantee amount is as follows:
Unit: 10,000 yuan
The guaranteed party's maximum guarantee amount is greater than the guaranteed amount. Does the guarantor hold the guarantee amount so far?
Guaranteed party Secured party Most recent assets Municipal company’s most recent proportion of related shares Guaranteed balance
Debt ratio Ratio of period net assets Guarantee
Anhui Guosheng Pharmacy directly holds shares
Chinese Health 80.40% 47,849.85 190,000.00 90.61% No Chain Co., Ltd. 100%
Anhui Quanfang Pharmaceutical has direct shares
Chinese Health 71.00% 439.34 5,000.00 2.38% No Limited Company 100%
Jiangsu Shenhua Pharmaceutical directly holds shares
Chinese Health 12.44% - 5,000.00 2.38% No
Ltd. 100%
Total - - - 48,289.19 200,000.00 95.38% -
Note 1: The scope of the guarantee limit includes existing guarantees, new guarantees, and extensions or renewals of existing guarantees;
Note 2: The latest net assets in the above table are the company's audited net assets in 2025; the latest asset-liability ratio of the secured party is calculated based on the financial data on December 31, 2025;
Note 3: Within the above estimated quota range and the validity period of the resolution, the company and its subsidiaries can adjust the guarantee quota among the guaranteed parties that meet the requirements (including but not limited to the above-mentioned guaranteed parties, existing subsidiaries within the scope of the current consolidated statements, and subsidiaries that will be newly established or included in the scope of the consolidated statements in the future);
Note 4: If there is any difference in the mantissa between the total in the table and the direct sum of each detail, it is due to rounding.
2. Basic information of the guaranteed party
- Anhui Guosheng Pharmacy Chain Co., Ltd.
Date of establishment: August 20, 2010
Registered address: Floor 8-11, Building A1, No. 123, Hebei Road, Luogang Street, Baohe District, Hefei City, Anhui Province (Baohe Economic Development Zone)
Registered capital: RMB 160 million
Legal representative: He Jiale
Business scope: Licensed items: drug retail; drug Internet information services; food sales; food Internet sales; third-class medical device operations; medical device Internet information services; road cargo transportation (not
(including dangerous goods); medical services (items that must be approved according to law, business activities can only be carried out after approval by relevant departments, specific business items are subject to approval documents or licenses from relevant departments) General items: food sales (only sales of pre-packaged food); food Internet sales (only sales of pre-packaged food); sales of health food (pre-packaged); sales of infant formula milk powder and other infant formula foods; sales of formulas for special medical purposes Sales of products; sales of Class I medical devices; sales of Class II medical devices; leasing of Class II medical devices; retail sales of edible agricultural products; sales of agricultural and sideline products; sales of household appliances; retail sales of hardware products; sales of electronic products; retail sales of cosmetics; sales of disinfectants (excluding hazardous chemicals); sales of sanitary products and disposable medical supplies; conference and exhibition services; non-residential real estate leasing; housing leasing; health consulting services (excluding diagnosis and treatment) Services); business management consulting; information technology consulting services; advertising design, agency; advertising production; advertising publishing; business agency services; traditional Chinese medicine clinic services (must be registered with the competent department of traditional Chinese medicine before engaging in business activities); Internet sales (except for the sale of goods that require a license); sales of maternal and infant products; sales of knitted textiles; sales of daily necessities; retail sales of sporting goods and equipment; sales of sanitary pesticides; bicycles and spare parts Sales of stationery supplies; sales of electric bicycles; retail sales of clothing and apparel; sales of outdoor supplies; retail sales of shoes and hats; retail sales of kitchenware, sanitary ware, and daily necessities; retail sales of jewelry; sales of toys; sales of cameras and equipment; sales of hairdressing accessories; sales of gold and silver products; purchase and sale of real estate Chinese herbal medicines (excluding Chinese herbal medicine pieces); retail sales of pet food and supplies; sales of tea sets (except for licensed businesses, items that are not prohibited or restricted by laws and regulations can be independently operated in accordance with the law)
Relationship with the company and other explanations: Anhui Guosheng Pharmacy Chain Co., Ltd. is a wholly-owned subsidiary of the company, and the company holds 100% of its equity. After inquiry, it is not a person subject to execution for breach of trust.
As of December 31, 2025/January to December 2025, the main financial indicators (audited) of Anhui Guosheng Pharmacy Chain Co., Ltd. are as follows:
Unit: RMB 10,000 Secured party Total assets Net assets Operating income Operating profit Net profit Anhui Guosheng Pharmacy Company
237,534.81 44,440.51 311,705.35 21,267.02 16,166.83 Lock Co., Ltd.
- Anhui Quanfang Pharmaceutical Co., Ltd.
Date of establishment: July 3, 2019
Registered address: 6th Floor, Building A1, No. 123, Hebei Road, Luogang Street, Baohe District, Hefei City, Anhui Province (Baohe Economic Development Zone)
Registered capital: RMB 40 million
Legal representative: Zhao Chunshui
Business scope: Licensed items: pharmaceutical wholesale; pharmaceutical Internet information services; pharmaceutical import and export; third-class medical device operations; medical device Internet information services; food sales; food Internet sales; disinfection equipment sales; urban distribution and transportation services (excluding dangerous goods); alcohol business (items subject to approval according to law, business activities can only be carried out after approval by relevant departments, specific business items are subject to approval documents or licenses from relevant departments) Certificate shall prevail) General items: Sales of Class I medical devices; Sales of Class II medical devices; Sales of health food (prepackaged); Sales of agricultural and sideline products; Wholesale of edible agricultural products; Sales of infant formula milk powder and other infant formula foods; Sales of formula foods for special medical purposes; Sales of maternal and infant products; Wholesale of cosmetics; Wholesale of medical masks; Sales of sanitary products and disposable medical supplies; Sales of daily masks (non-medical); Medical Wholesale of personal protective equipment; sales of disinfectants (excluding hazardous chemicals); sales of glasses (excluding contact lenses); sales of labor protection products; sales of special labor protection products; wholesale of daily necessities; sales of daily necessities; sales of office supplies; wholesale of stationery; sales of packaging materials and products; sales of household appliances; health consulting services (excluding diagnosis and treatment services); conference and exhibition services; information consulting services (excluding licensing information consulting) Consulting services); business management consulting; loading and unloading; non-residential real estate leasing; general cargo warehousing services (excluding hazardous chemicals and other items that require license approval); import and export of goods; technology import and export; technical services, technology development, technology consulting, technology exchange, technology transfer, technology promotion; advertising design, agency; advertising production; advertising release (except for licensed business, you can independently operate projects that are not prohibited or restricted by laws and regulations in accordance with the law)
Relationship with the company and other explanations: Anhui Quanfang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of the company, and the company holds 100% of its equity. After inquiry, it is not a person subject to execution for breach of trust.
As of December 31, 2025/January to December 2025, the main financial indicators of Anhui Quanfang Pharmaceutical Co., Ltd. (audited) are as follows:
Unit: RMB 10,000
Secured party Total assets Net assets Operating income Operating profit Net profit Anhui Quanfang Pharmaceutical Co., Ltd. 15,231.42 4,417.62 26,872.67 -473.93 -354.46
- Jiangsu Shenhua Pharmaceutical Co., Ltd.
Date of establishment: December 28, 2000
Registered address: No. 188, Shenhua Avenue, Jinhu County, Jiangsu Province
Registered capital: RMB 172 million
Legal representative: Yin Jun
Business scope: production of tablets, hard capsules, granules, mixtures, oral solutions, powders, raw materials, pharmaceutical excipients (xanthan gum), and health food; R&D and production of fungal raw materials; extraction of traditional Chinese medicine; sales of the above self-produced products of the company. Production and sales of biological polysaccharide series products (limited to wolfberry polysaccharide, cordyceps polysaccharide, Ganoderma lucidum polysaccharide, and monkey mushroom polysaccharide), and sales of xanthan gum and amino acid series products (except for the above-mentioned products that require relevant licenses for food and drug production and operation). Sales of sodium glutamate and starch sugar food additives. Retail sales of medicines, Class I medical devices, Class II medical devices, prepackaged food, dairy products (including infant formula milk powder), health food, and cosmetics (limited to branch operations). Production of medical masks; production of Class II medical devices; production of protective equipment for medical staff (Class II medical equipment); retail of medical masks; wholesale of medical masks; production of daily masks (non-medical); sales of daily masks (non-medical); retail of protective equipment for medical staff; wholesale of protective equipment for medical staff; wholesale of Class II medical equipment. (If it does not involve state-owned trade management commodities, but involves quota or license management commodities, the application shall be handled in accordance with relevant national regulations). (Projects that are subject to approval according to law can only be carried out with the approval of relevant departments) Licensed projects: Food additive production (Projects that are subject to approval according to law can only be carried out with the approval of relevant departments. Specific business projects are subject to the approval results) General projects: technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion (except for projects that are subject to approval according to law, business activities can be carried out independently with a business license in accordance with the law)
Relationship with the company and other explanations: Jiangsu Shenhua Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of the company, and the company holds 100% of its equity. After inquiry, it is not a person subject to execution for breach of trust.
As of December 31, 2025/January to December 2025, the main financial indicators (audited) of Jiangsu Shenhua Pharmaceutical Co., Ltd. are as follows:
Unit: RMB 10,000 Secured party Total assets Net assets Operating income Operating profit Net profit Jiangsu Shenhua Pharmaceutical Co., Ltd.
29,309.11 25,663.37 19,769.10 3,116.49 2,617.71Company
3. Main contents of the guarantee agreement
As of the announcement date, the agreement related to this guarantee has not yet been signed (except for past agreements that are still valid). When the actual loan and guarantee occur, the guarantee amount, guarantee period, guarantee rate and other contents will be determined by the company and its relevant subsidiaries and lending banks and other financial institutions within the above amount through joint negotiation and selection, and relevant contracts will be signed. Related guarantee matters shall be subject to the officially signed guarantee document.
4. Review procedures and related opinions
- Opinions of the Audit Committee
After deliberation, the Audit Committee believes that the estimated amount of this guarantee complies with relevant laws and regulations such as the Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies, as well as the provisions of the Articles of Association and the Company's External Guarantee Management System. The guaranteed operating conditions of the subsidiaries at all levels are stable, with excellent asset quality and good solvency. This guarantee will not damage the company's interests and will not have an adverse impact on the company and its subsidiaries. The Audit Committee unanimously agreed on the estimated guarantee amount for subsidiaries and agreed to submit the proposal to the company's board of directors for review.
- Board of Directors review
The company held the 14th meeting of the fifth board of directors on April 23, 2026, and reviewed and approved the "Proposal on the Estimated Guarantee Amount for Subsidiaries in 2026." The board of directors believes that the company provides guarantees for subsidiaries at all levels to meet the financial needs of enterprise development and has fulfilled legal procedures. This guarantee does not involve counter-guarantee. After a comprehensive assessment of the asset quality, operating conditions, industry prospects, solvency, and credit status of each secured party, the board of directors believes that each secured party is currently in good operating condition, has sufficient funds, and has the ability to repay its debts. Therefore, the board of directors agreed on the estimated amount of guarantees provided to subsidiaries, and this proposal needs to be submitted to the shareholders' meeting for review.
5. Cumulative number of external guarantees and number of overdue guarantees
After this guarantee comes into effect, the total amount of guarantees provided by the company and its subsidiaries is RMB 2,000,000, accounting for 95.38% of the company's latest audited net assets. As of December 31, 2025, the actual external guarantee balance of the company and its subsidiaries totaled 610.6008 million yuan (all of which were the company's guarantees for subsidiaries within the scope of the consolidated statements), accounting for 29.12% of the company's latest audited net assets. The company and its subsidiaries have no overdue external guarantees, no guarantees related to litigation or guarantees for the amount of losses that should be borne due to being judged to have lost the lawsuit, and no guarantees have been provided to shareholders, actual controllers and their related parties.
6. Documents for reference
Resolution of the 14th meeting of the fifth board of directors;
Resolution of the 12th meeting of the Audit Committee of the fifth session of the Board of Directors.
Announcement is hereby made.
Anhui Chinese Health Pharmaceutical Co., Ltd. Board of Directors April 25, 2026